<DOC>
	<DOCNO>NCT02973464</DOCNO>
	<brief_summary>This study evaluate safety availability oral valganciclovir ( VGC ) 450mg daily begin within 10 day renal transplantation , till Day 100 posttransplant . Compare guideline effective antiviral prophylaxis , investigator divide patient three group random . One third oral VGC 450mg daily mention ; one third oral VGC 900mg daily ; one third intravenous GCV 5mg/kg daily within first 14 day posttransplant , continue oral GCV 1g 3 time daily till Day 100 posttransplant ; adjust per renal function agent .</brief_summary>
	<brief_title>The Strategy Prevention Renal Post-transplant Cytomegalovirus Infection Among Chinese Population</brief_title>
	<detailed_description>Human Cytomegalovirus ( CMV ) , kind Î²-hepersvirus , common opportunistic pathogen . The ubiquity CMV infection human being verify ; CMV-IgG seropositive rate 97 % among healthy population , state latent infection . When immunosuppressed , renal transplant recipient , incidence CMV infection disease increase obviously . The posttransplant CMV infection would induce allgraft rejection , impact allgraft recipient survival , well contribute serious complications.Many study show give effective antivirus drug transplantation benifit recipient . Nowadays , strategy intravenous GCV GCV 5mg/kg daily oral GCV 1g 3 time daily , recommend treatment CMV disease posttransplantation.Resent date show VGC oral prodrug GCV . When VGC absorb intestinal wall liver , rapidly metabolize ganciclovir . As contemporary study , IV GCV 5mg/kg/day approach similar area curve VGC 900mg daily . The bioavailability ganciglovir valganciclovir 10 time GCV oral . For recipient , oral therapy safety convinient , reduce frequent hospitalization . As many research , indicate oral VGC 450mg daily also reduce adverse event result posttransplant CMV infection , significantly statistic difference compare oral VGC 900mg daily . Simultaneously , low dose could decrease risk leukopenia ease burden recipient . This study single-center , prospective , observational , corhort study . According inclusion exclusion criterion , investigator recruit 450 patient . And every one follow least 12 month unless death graft loss , specific duration baseline , weekly within first 3 month posttransplantation , month 4 , month 5 , month 6 , month 9 , month 12 . Recipients follow CMV-DNA , CMV-pp65 , CMV antigenemia , blood routine test , urinalysis , liver function , renal fuction chest X-ray film . Inverstigators collect date recipient : general condition , age , sex , weight ; primary reason transplant ; donor/recipient CMV serostatus ; biopsy-prove acute rejection ; opportunistic infection ; NODAT ; etc . And Chi-square Fisher 's exact test use appropriate compare categorical variable , consider statistically significant 2-sided P-value &lt; 0.05 . Definitively , conclusion come verify safety availability protocol .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>1.65 year old &gt; =Age &gt; =18 year old , male female 2.Renal transplantation first time 3.CMV serology donorpositive ( D+ ) recipientpositive ( R+ ) renal transplant recipients 1.Those allergic resistant Acyclovir , Valaciclovir , Ganciclovir , Valganciclovir 2.HIV , hepatitis B hepatitis C patient 3.Not pregnancy lactation , pregnancy test negative , promise pregnancy treatment 4.Male pregnant partner ; lactation 5.Suspected CMV disease enrolment 6.Use antiCMV therapy within 30 day prior study 7.Multiple organ transplantation 8.Uncontrolled diarrhea evidence malabsorption 9.Liver function test &gt; 3 time upper level normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>